Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

Br J Dermatol. 2019 Jul;181(1):196-197. doi: 10.1111/bjd.17703. Epub 2019 Mar 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Clinical Trials, Phase III as Topic
  • Dermatitis, Atopic / diagnosis
  • Dermatitis, Atopic / drug therapy*
  • Dermatitis, Atopic / immunology
  • Humans
  • Interleukin-4 Receptor alpha Subunit / antagonists & inhibitors
  • Interleukin-4 Receptor alpha Subunit / immunology
  • Severity of Illness Index
  • Skin / drug effects*
  • Skin / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • IL4R protein, human
  • Interleukin-4 Receptor alpha Subunit
  • dupilumab